Pharmaceuticals, Biotechnology and Life Sciences
Lyfebulb and Novo Nordisk have join again to support international patient entrepreneurs who develop innovative ideas and concepts aimed to positively empower and impact the lives of people living with type 1 or type 2 diabetes – and ultimately our societies.
Allergan’s wholly-owned subsidiary, Allergan Sales LLC has acquired Keller Medical, a privately held medical device company and developer of the Keller Funnel.
Celgene Corporation and Agios Pharmaceuticals have reported new efficacy and safety data from the ongoing Phase 1 dose-escalation and expansion study evaluating investigational oral Idhifa (enasidenib) in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and an isocitrate dehydrogenase-2 (IDH2) mutation.
European Commission has granted marketing authorisation for Novo Nordisk’s Refixia for the treatment of adolescents and adults with haemophilia B.
Bristol-Myers Squibb and Novartis have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in combination with Mekinist (trametinib), as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).
CTI BioPharma has announced the pricing of an underwritten public offering of 22,500 shares of its Series N-3 Preferred Stock, offered at a price to the public of $2,000 per share of Series N-3 Preferred Stock (the “Offering”).
European Commission (EC) has approved the inclusion of Treatment-free Remission (TFR) data in the Novartis’s Tasigna (nilotinib) Summary of Product Characteristics (SmPC).
Vertex Pharmaceuticals Incorporated has reached an agreement with the Health Service Executive (HSE) in the Republic of Ireland to fund Orkambi (lumacaftor/ivacaftor).
BioMarin Pharmaceuticalsaid today that it got from the European Commission (EC) a grant for Brineura (cerliponase alfa), the first treatment approved in the European Union (EU) for tripeptidyl peptidase 1 (TPP1) deficiency.
Drug delivery technology market grows from $1,179.20 billion to $1,669.40 billion at a CAGR of 7.2% from 2016-2021. Oral drug delivery segment is expected to account for the largest share while hospitals segment is expected to account for the largest share of the market and Asia is expected to be fastest-growing region.